Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|March 31, 2019
Prospective Clinical Sequencing of Adult GliomaSiyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Journal of Neuro-Oncology|April 6, 2018
Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcomeAikaterini Kotrotsou, Ahmed Elakkad, Jia Sun, et al.
Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with afliberceptJohn F de Groot, Yuji Piao, Hai Tran, et al.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Neuro-Oncology|May 21, 2024
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncologyRifaquat Rahman, Diana D Shi, Zachary J Reitman, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
Neuro-Oncology|February 25, 2025
Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapyKatie Lin, Christopher Zou, Akane Hubbard, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|March 31, 2019
Prospective Clinical Sequencing of Adult GliomaSiyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Journal of Neuro-Oncology|April 6, 2018
Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcomeAikaterini Kotrotsou, Ahmed Elakkad, Jia Sun, et al.
Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with afliberceptJohn F de Groot, Yuji Piao, Hai Tran, et al.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Neuro-Oncology|May 21, 2024
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncologyRifaquat Rahman, Diana D Shi, Zachary J Reitman, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
Neuro-Oncology|February 25, 2025
Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapyKatie Lin, Christopher Zou, Akane Hubbard, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
Pageof 13